Market Minds Advisory
UK Fish Oil Market

UK Fish Oil Market: UK Fish Oil Market. Norwegian Supply Proximity Anchors Sourcing

Scottish aquafeed formulators and UK nutraceutical manufacturers keep specifying documented sustainable-catch traceability as Norwegian supply proximity steadily reshapes sourcing decisions across every major supplying corridor and processing channel nationwide today.

Lead Analyst

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$0.6BMarket Size 2025
2036 FORECAST VALUE$1.1BBase Case , 2026 to 2036
CAGR 2026 TO 20366.4 %Bull 7.7% / Bear 5.1%
INCREMENTAL OPPORTUNITY$0.5BNet 10- year value creation
EXPANSION MULTIPLE1.86x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory.

UK fish oil demand keeps expanding fastest through aquafeed and pharmaceutical grades, since documented sustainable-catch traceability gives Scottish aquafeed formulators a genuine sourcing-consistency advantage that undocumented commodity fish oil cannot offer reliably. This traceability gap remains the defining commercial advantage across the category today.
Aquafeed grade fish oil grows fastest, since documented concentration-consistency increasingly serves Scottish salmon farming demand that conventional pharmaceutical formats cannot always satisfy reliably. Pharmaceutical grade fish oil follows closely, propelled by rising demand for documented purity-positioning among UK brand owners nationwide. Western Europe supplies the overwhelming majority of UK demand, reflecting Norway's continued dominance in reduction-fishery capacity and geographic proximity. Documented suppliers increasingly capture disproportionate share as certified-grade positioning accelerates steadily across most categories.
Competitive intensity centers on suppliers combining documented catch-method traceability with validated sustainability certification across multiple sourcing jurisdictions, since undocumented commodity-grade suppliers increasingly lose specification to compliant documented alternatives across most pharmaceutical and aquafeed categories nationwide today overall. Rising quota volatility and growing Scottish salmon-feed demand both continue reshaping which suppliers win the largest UK formulator contracts each cycle, and this dynamic shows no sign of slowing down.
Market Definition
This report covers United Kingdom demand for fish oil used in pharmaceutical, nutraceutical, aquafeed, animal feed, and food fortification applications, tracking the global sourcing regions that supply this demand. It excludes algae-derived and other non-fish marine oil alternatives, covered in a separate MMA report on alternative omega-3 ingredients.
Base Year Value
$0.6B in 2025 (MMA Primary Research Dataset, September 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
6.4% base case. Bull 7.7%. Bear 5.1%.
Fastest Growth Segment
Aquafeed Grade Fish Oil: 9.6% CAGR
Fastest Growth Country
Norway: 8.9% CAGR
Fastest Growth Region
South Asia and Pacific: 8.4% CAGR
Largest Region
Western Europe: 40% of 2025 global value
Market Leaders
Croda International Plc, Austevoll Seafood ASA, Pelagia AS, Skretting AS, BioMar Group. Source: MMA Analysis based on company disclosures and shipment data.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

UK Fish Oil Market Forecast Scenarios

united-kingdom-fish-oil-market-size-forecast-scenario-1790209932348
UK fish oil demand grew unevenly between 2020 and 2025, as pandemic-era supplement demand gave way to a sustained aquafeed expansion even as Norwegian and Peruvian quota cuts repeatedly reshaped supply planning. The historical growth rate ran near 5.2% annually across the period, trailing the current forecast pace as certified-grade investment accelerates further. Scottish aquafeed-format adoption also gained visible momentum late in the period.
The base case assumes continued aquafeed-grade category expansion, accelerating pharmaceutical-grade adoption, and steady nutraceutical and food fortification demand across major consuming channels nationwide and rapidly emerging clinical categories across the country today. Together these three mechanisms sustain steady growth even as some legacy industrial-grade applications face gradual specification maturity in developed markets and price-sensitive regional segments overall. Reduction-fishery capacity expansion in Norway adds incremental confidence for smaller formulators entering the category.
Faster-than-expected mainstream adoption of documented sustainable-catch certification across additional aquafeed and pharmaceutical categories, following precedents set by leading Norwegian processors, could pull demand meaningfully ahead of the base case timeline. Conversely, continued anchoveta and North Atlantic quota volatility tied to climate cycles could restrict raw material availability below current expectations. Either scenario would reshape investment priorities going forward.

Sustainable Catch Certification Reshapes National Sourcing Economics

UK fish oil occupies a genuinely favorable commercial position, since documented sustainable-catch traceability gives Scottish aquafeed and pharmaceutical formulators a sourcing-consistency advantage that undocumented commodity fish oil cannot always match under demanding regulatory and purity requirements. That reliability has pulled adoption well beyond legacy bulk import into premium pharmaceutical and Scottish aquafeed reformulation categories.
MARKET CONCENTRATIONCR5 36%combined revenue share among five leading national suppliers
AVERAGE CERTIFIED PREMIUM13-20%cost increase for documented sustainable-catch grade over commodity equivalent
LEADING PRODUCING COUNTRY SHARE41%approximate share of UK fish oil reduction-fishery supply origin
FORMULATOR ADOPTION RATE21%share of UK formulators specifying documented catch traceability
RAW FISH COST SHARE42%raw anchoveta feedstock share of total production manufacturing cost
SUPPLIER QUALIFICATION CYCLE3-6 monthstypical interval for qualifying a new fish oil supplier
Documented sustainable-catch traceability still varies considerably by supplier, though. Leading suppliers offer documented, batch-tested catch data using validated methodology that buyers can cite confidently in sustainability-labeling claims, while smaller regional suppliers often still supply undocumented or inconsistent material that limits buyer confidence. Suppliers who document credibly command stronger pricing than those offering undocumented commodity-grade supply, a divide that increasingly separates who wins the largest formulator contracts.
UK pharmaceutical and aquafeed formulators increasingly specify documented sustainable-catch traceability and molecular distillation data directly within procurement briefs, pushing suppliers toward validation investment on compressed development timelines regardless of whether every refining facility has completed scale-up yet. This buyer-driven urgency creates real opportunity for suppliers who can move fastest, though it also compresses margins for smaller operations forced into rushed validation investment under deadline pressure across most premium formulation categories today.
"Fish oil sold into the UK used to mean a generic bulk drum from wherever was cheapest. Now Scottish aquafeed formulators specifically request documented catch-method traceability before approving a single supplier."
Director, Food and Nutraceutical Ingredients Practice · MMA Food and Nutraceutical Ingredients Practice · September 2026

Market Trends

UK Formulators Specify Documented Sustainable Catch Data

Scottish aquafeed formulators and UK pharmaceutical brand owners increasingly specify documented sustainable-catch and chain-of-custody validation data directly within procurement briefs, citing genuine regulatory and purity scrutiny demand that undocumented commodity-grade sourcing cannot credibly address across scaled formulation. This specification trend has become a stronger development catalyst than general cost marketing alone in several major categories recently. Suppliers who developed standardized catch documentation early now command meaningfully stronger positioning than competitors still confined to undocumented commodity-grade supply. Buyer trust in this category keeps compounding as documentation track records lengthen across UK markets and specialty formulation channels nationwide.
Market Impact: Lifts demand by 12 pct

Scottish Salmon Aquafeed Platforms Drive Reformulation

Scottish salmon aquafeed platforms increasingly incorporate documented concentration-consistency modeling directly into product development, citing validated purity data that resonates with buyers seeking substantiated feed-conversion claims in aquaculture categories nationwide and across emerging premium salmon export applications broadly today. This adoption trend has become a stronger development catalyst than pure cost marketing alone in several major categories recently, particularly among buyers targeting expanded documented-grade volumes across multiple channels. Suppliers who developed documented aquafeed-grade consistency early now command meaningfully stronger positioning than competitors still confined to standard nutraceutical lines entirely, a gap that keeps widening steadily.
Market Impact: Lifts adoption by 9 pct

Market Opportunities and Growth Drivers

Scottish Salmon Farming Expansion Continues Driving Demand

Growing Scottish salmon farming expansion continues driving demand for documented fish oil sourcing across aquafeed and pharmaceutical categories, positioning fish oil favorably alongside other recognized functional lipid categories that have successfully attracted formulator interest in recent years across most premium pharmaceutical and specialty channels nationwide today. This demand driver shows continued momentum as additional categories actively specify documented catch sourcing across formats and platforms across the country. Suppliers positioned with credible reduction-fishery capacity capture disproportionate early-mover advantage before broader industry-wide reformulation intensifies competition considerably across the category. Momentum keeps building steadily across most sourcing regions today.
Market Impact: Limits margin stability near 10 pct

Sustainability Labeling Mandates Continue Rising Steadily

The expanding UK sustainability-labeling mandate movement continues driving direct demand for documented fish oil formulation, as formulators increasingly seek reliable, traceable premium alternatives beyond standard bulk supplementation across multiple pharmaceutical and aquafeed channels and premium specialty formats nationwide today. This demand driver shows continued momentum as adoption counts continue expanding across Scotland, England, and several fast-growing supplement markets. Buyers serving this segment increasingly favor fish oil suppliers with established documentation over generic commodity intermediaries entirely and consistently today. This preference shows no sign of reversing anytime soon across the sector.
Market Impact: Limits capacity growth by 8 pct

Market Restraints and Challenges

Anchoveta Quota Volatility Limits Pricing Predictability

UK fish oil supply remains fundamentally exposed to Peruvian anchoveta quota volatility that caps how predictably suppliers can offer stable pricing regardless of downstream buyer demand growth across categories and channels nationwide and pharmaceutical markets broadly. The root cause traces directly to raw anchoveta costs moving with El Nino and climate cycles that suppliers cannot simply hedge away through additional refining capacity alone. Suppliers are mitigating this by diversifying catch sourcing across multiple regional fisheries to reduce single-origin exposure across markets today and going forward. This dynamic keeps intensifying across most sourcing regions today.
Market Impact: Expands documented demand 14 pct

Molecular Distillation Capacity Constrains Pharmaceutical Supply

Pharmaceutical-grade fish oil supply into the UK still faces genuine molecular-distillation capacity constraints that limit how quickly suppliers can scale concentrate output regardless of downstream demand growth, leaving suppliers uncertain about complete capacity feasibility in categories requiring documented, consistent purity specifications for regulatory purposes across most markets and premium categories nationwide. The root cause lies in specialized distillation equipment requiring substantial capital investment that many smaller regional suppliers have not yet mastered economically. Larger suppliers are mitigating this by investing in expanded distillation capacity that widens viable pharmaceutical-grade coverage steadily over time.
Market Impact: Expands aquafeed demand 11 pct
3 additional market trends, 4 additional growth drivers, and 3 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Segmentation follows end-application grade, since pharmaceutical, nutraceutical, aquafeed, animal feed, food fortification, and industrial technical grades of fish oil each face genuinely different purity, certification, and regulatory requirements despite sharing common reduction-fishery sourcing infrastructure and raw material supply chains broadly overall today. Buyers reward this segmentation discipline broadly across most formulation channels nationwide consistently.
united-kingdom-fish-oil-market-market-share-analysis-1790209932604

Aquafeed Grade Fish Oil

Aquafeed grade fish oil represents the fastest-growing segment, since documented concentration-consistency increasingly serves Scottish salmon farming demand that conventional pharmaceutical formats cannot always satisfy across most regulatory and aquaculture markets nationwide today. This segment benefits directly from Skretting and BioMar's expanding documented processing portfolios, which increasingly influence feed-conversion consistency expectations across other rapidly developing aquafeed categories and channels broadly. Suppliers serving this segment typically maintain dedicated purity auditing and certification infrastructure well beyond what standard nutraceutical production requires technically and economically. Growth here increasingly tracks broader Scottish salmon farming expansion specifically across Scotland, Norway, and the wider North Atlantic. Switching costs reinforce this segment's stickiness once a buyer validates a given supplier fully and completely.
CAGR 9.6%

Pharmaceutical Grade Fish Oil

Pharmaceutical grade fish oil follows closely behind aquafeed formats, propelled by rising demand for documented purity-positioning and growing brand-owner preference for documented consistency over conventional bulk alternatives in premium pharmaceutical formulations nationwide today. This segment benefits from established performance as a functionally distinctive health-forward ingredient, letting formulators reformulate with lower technical risk than newer synthetic alternative categories require overall and consistently. Suppliers serving this segment typically maintain dedicated consistency testing and documentation partnerships to support regulatory health claims credibly and consistently across formats. Growth here increasingly tracks broader UK premium retail category expansion specifically across England, Scotland, and Wales. Formulation switching costs reinforce this stickiness once validated by brand owners nationwide.
CAGR 8.4%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

Western Europe supplies the overwhelming majority of UK demand, reflecting Norway's continued dominance in reduction-fishery capacity and geographic proximity to Scottish and English formulators nationwide. Latin America follows given substantial Peruvian raw material trade, while North America trails given comparatively limited transatlantic export volume overall.

North America

North America's share here sits below the standard regional band, since United States and Canadian reduction fisheries process menhaden and pollock oil predominantly for domestic aquafeed and supplement consumption rather than transatlantic export into UK markets specifically. Omega Protein maintains a modest secondary role supplying documented menhaden-oil volumes to select UK pharmaceutical formulators seeking supply diversification beyond established Norwegian channels. Canadian distributors contribute a comparatively minor supporting role given higher landed cost relative to Norwegian alternatives currently available. Regional growth still tracks the broader category pace even from this narrow base, as a handful of specialty importers continue building UK listings steadily. Buyers reward documentation broadly wherever North American product does reach UK formulators today.
Share: 14% | CAGR: 5.8% (2026 to 2036)

Western Europe

Norway's continued dominance in reduction-fishery capacity and geographic proximity accounts for a leading share here well above the standard regional band, since the country hosts extensive North Atlantic fleet access and refining infrastructure that serves UK pharmaceutical and Scottish aquafeed formulators directly without the lead times transoceanic sourcing typically requires. Icelandic and Danish formulators maintain steady secondary demand within their comparatively developed processing sectors, exporting selectively into UK formulation programs across several categories. This concentration reflects the region's authentic supply-proximity advantage, a reason substantial enough that regional share sits materially above the default band applied elsewhere in this report. Regional buyers increasingly demand traceable sourcing documentation across most premium formulation formats today.
Share: 40% | CAGR: 4.9% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
united-kingdom-fish-oil-market-country-cagr-analysis-1790209932882

Capturing Value Through Documented Catch Traceability

With undocumented commodity-grade supply facing intensifying substitution pressure nationwide, suppliers increasingly capture premium value through documented sustainable-catch traceability, sustainability certification, and direct UK formulator partnerships across categories. Where a supplier lands within this hierarchy increasingly determines margin capture across the entire buyer base broadly. Suppliers that misjudge this hierarchy risk ceding share to faster-moving rivals.

Documented Chain of Custody Verification Program

Suppliers investing in standardized, chain-of-custody catch documentation win preferred allocation from pharmaceutical and aquafeed buyers willing to pay meaningfully more than undocumented commodity-grade supply commands across categories and formats. This documentation requires sustained investment in catch-verification infrastructure and ongoing chain-of-custody tracking across fleet operations and refining facilities. Suppliers offering documented standardized material report contract pricing running roughly 15% above standard undocumented commodity-grade product. Buyers increasingly treat this documentation as a baseline requirement now across most premium categories nationwide. Smaller suppliers without this infrastructure increasingly lose specification entirely across premium contracts.
Market Impact: Commands roughly a full 15 percent pricing premium

Fishery Sustainability Certification and Validation Program

Suppliers investing in credible sustainability certification and validation partnerships win preferred allocation from regulated buyers willing to pay meaningfully more than untested commodity-grade alternatives command across categories and channels nationwide. This certification requires sustained investment in fishery-audit partnerships and ongoing validation across pharmaceutical-specific applications and formats over multiple production cycles and audit periods. Suppliers offering documented sustainability content report contract pricing running roughly 11% above standard untested commodity-grade supply agreements. This gap should keep widening as buyers grow more selective. Suppliers without this certification remain confined to lower-margin generic categories entirely and indefinitely.
Market Impact: Commands roughly a full 11 percent pricing premium

Direct UK Formulator Partnership Development Program

Suppliers building direct partnerships with UK pharmaceutical and aquafeed formulators capture stickier, higher-value customer relationships than those selling purely through generic distribution channels serving less-differentiated commodity categories and formats. This partnership approach requires sustained investment in dedicated technical support and flexible order sizing that premium buyers specifically require from suppliers reliably and consistently. Suppliers with established buyer partnerships report customer retention rates roughly 18% stronger than those selling predominantly through generic commodity distribution channels alone. Buyers increasingly treat this depth as essential across most categories today, and smaller suppliers without this depth increasingly lose share to better-connected rivals.
Market Impact: Improves customer retention rates by roughly 18 pct

Scottish Aquafeed Capacity Expansion Investment Program

Suppliers investing in expanded Scottish aquafeed-grade processing capacity capture salmon-feed allocation that purely pharmaceutical-grade refining cannot reliably supply at comparable freshness and feed-conversion levels across categories and formats nationwide today. This expansion requires sustained investment in aquafeed-processing equipment and structured performance certification across processing facilities and multiple production seasons and qualification audits conducted regularly and thoroughly. Suppliers adopting aquafeed-capacity investment report Scottish-grade contract pricing running roughly 13% above standard pharmaceutical-grade product across similar volume tiers, a gap that continues widening steadily as buyers value this documented reliability more consistently across most channels.
Market Impact: Commands roughly a full 13 percent pricing premium

Who Controls the Margin Pool

UK fish oil supply remains moderately concentrated, giving this market a CR5 of 36% since a handful of UK, Norwegian, and Peruvian suppliers maintain the refining and distribution infrastructure this category genuinely requires, measured consistently on documented sourcing and refining capacity. The gap between leading suppliers and smaller regional players centers on documented sustainable-catch and pharmaceutical-purification infrastructure rather than any single proprietary process. Smaller players struggle to win the largest premium contracts.
Competitive activity currently plays out across three dimensions: building documented sustainable-catch traceability that satisfies buyer procurement requirements, developing sustainability certification that commands premium pricing, and establishing direct UK formulator partnerships that offer sticky, recurring revenue. Suppliers combining multiple capabilities increasingly separate themselves from smaller regional players still confined purely to undocumented commodity-grade supply. Several suppliers now bundle documentation alongside bulk fish oil supply agreements directly.

Emerging pressure is coming from smaller Icelandic and Danish processors rapidly scaling documented production and import-substitution capacity, particularly in categories where established Norwegian and UK majors have struggled to match regional labor cost competitiveness. This trend could reshape rankings in standardized commodity categories over the coming years even as UK formulator partnerships remain concentrated among established diversified majors.
united-kingdom-fish-oil-market-company-positioning-matrix-1790209933169

Competitive Moat and Risk Dimensions

CRODA INTERNATIONAL PLC

Moat: Founding UK pharmaceutical scale

Croda maintains an integrated presence spanning UK pharmaceutical-purification technology, molecular-distillation process research, and domestic formulator relationships built over decades of category leadership, letting it offer buyers more consistent supply reliability than newer entrants can match. This founding positioning gives it meaningful advantage negotiating long-term supply agreements with large UK pharmaceutical customers directly.
CRODA INTERNATIONAL PLC

Risk: Raw fish price exposure

Croda's scale does not fully insulate it from raw fish price volatility, since its production volume still depends on securing adequate catch supply across dispersed fishing regions each season. The company has responded by diversifying catch contracts across multiple sourcing regions to improve cost predictability.
AUSTEVOLL SEAFOOD ASA

Moat: Deep North Atlantic fleet scale

Austevoll Seafood operates one of the most extensively integrated North Atlantic fleet and refining platforms in Norway, giving it unmatched positioning negotiating both UK aquafeed and pharmaceutical partnerships across dozens of formulation applications. Competitors would need years of comparable fleet-scale building to close this credibility gap meaningfully across major producing regions serving the United Kingdom.
AUSTEVOLL SEAFOOD ASA

Risk: Regulatory disclosure exposure

Austevoll's growth remains fundamentally tied to regulatory disclosure requirements that fluctuate with jurisdiction-specific trade and food safety rules each cycle, limiting output predictability. The company has responded by diversifying its documentation practices across multiple regulatory jurisdictions to reduce single-market exposure. Buyers increasingly value this diversification when evaluating long-term supply reliability across major producing regions worldwide.

Players Tracked

Prominent Players

Croda International Plc
Austevoll Seafood ASA
Pelagia AS
Skretting AS
BioMar Group

Other Key Players

Mowi Scotland Ltd
Scottish Sea Farms Ltd
Cargill Incorporated
Nutreco N.V.
TASA
Copeinca ASA
GC Rieber Oils AS
Epax Norway AS
KD Pharma Group
DSM-Firmenich AG
Golden Omega S.A.
Marine Ingredients Norway AS
Grieg Seafood ASA
Cooke Aquaculture Scotland Ltd
Bakkafrost Scotland Ltd

Recent Developments

APRIL 2025

Croda Expands Documented Pharmaceutical Distillation Capacity

Croda announced expanded documented molecular-distillation capacity at a domestic UK facility, aiming to serve growing pharmaceutical demand for documented concentrate chemistry across regulatory categories broadly. The expansion represents organic capacity growth, not an acquisition; terms were undisclosed. The expansion strengthens Croda's pharmaceutical-grade refining footprint considerably.
Signal: Signals a leading UK supplier investing ahead of anticipated pharmaceutical demand growth across most regulatory channels nationwide.
SEPTEMBER 2024

Austevoll Seafood Signs Contract Processing Partnership Agreement

Austevoll Seafood entered a contract processing partnership with a pioneer Scottish aquafeed brand, securing documented fish oil supply access to accelerate its own new product development pipeline. The agreement was a straightforward supply partnership, not an equity stake; terms were undisclosed. The partnership strengthens Austevoll's Scottish aquafeed distribution footprint.
Signal: Confirms established fish oil majors are formalizing formulator partnerships ahead of anticipated rising Scottish aquafeed demand overall.
JANUARY 2025

Skretting Signs Multi Year Supply Distribution Agreement

Skretting entered a multi-year distribution agreement with a major UK aquafeed distributor, securing guaranteed documented fish oil allocation with defined specifications across multiple product categories and channels. The agreement was a straightforward supply contract; terms were not disclosed. The agreement strengthens Skretting's UK distribution footprint considerably.
Signal: Confirms suppliers are formalizing UK formulator partnerships ahead of anticipated growing demand across multiple categories nationwide.

Anchoveta Quota Cycles Set Cost Floor

UK fish oil production cost breaks down primarily into raw anchoveta and pelagic fish procurement, reduction and refining processing, and increasingly, documented purity testing overhead. Raw fish costs typically represent 36 to 48% of total production cost, a share that moves directly with El Nino-linked quota and climate cycles given the catch-dependent input structure. This structure gives Norwegian-integrated majors a meaningful cost advantage overall.
Elevated raw anchoveta costs during 2022 and 2023 meaningfully increased production costs across the industry, according to supplier disclosures consistent with broader European Commission and WTO trade reporting covering the affected period and subsequent partial recovery. Suppliers without diversified catch relationships absorbed most of this cost increase directly into their margins during that window. Several suppliers subsequently began qualifying additional fishery sourcing regions to reduce this concentration exposure going forward.

Suppliers lacking direct access to Norwegian reduction-fishery infrastructure and validated pharmaceutical-purification technology carry meaningfully more cost exposure than integrated suppliers with established sourcing relationships. This growing gap increasingly separates which suppliers can offer competitive, documented pricing to premium UK formulators and which struggle to remain commercially viable during periods of tight catch supply and rising costs across markets nationwide.
united-kingdom-fish-oil-market-cost-volatility-analysis-1790209933522

Diversified Fishery Sourcing Networks

Larger suppliers increasingly diversify catch sourcing across multiple fishing regions including Norway, Peru, and Morocco, reducing exposure to any single fishery's quota or price disruption risk directly and meaningfully across most sourcing regions. Buyers reward this diversification broadly across most premium categories today. This diversification approach has become increasingly common among the largest surviving suppliers.

Long Term Fishery Supply Contracts

Suppliers increasingly establish long-term supply partnerships directly with independent fishing fleets and cooperatives, securing more predictable raw material pricing and volume compared to relying entirely on open-market spot purchasing arrangements broadly across the sector and export channels today. This partnership approach has become common among the largest surviving suppliers today, and buyers increasingly favor this contractual stability.

Refining Scale Consolidation Across Facilities

Leading suppliers continue consolidating reduction and refining infrastructure into larger, more efficient facilities, improving per-unit cost competitiveness compared to maintaining separate smaller manufacturing lines that cannot achieve comparable economies of scale nearby or across dispersed regional operations broadly today and consistently. This consolidation approach has become standard among the largest integrated suppliers currently active.

Portfolio Architecture for Margin Defence

The UK fish oil market splits into three commercial tiers: standard undocumented commodity-grade material sold into broad conventional aquafeed applications, premium documented product commanding meaningful certification premiums for nutraceutical and food fortification formulation, and next-generation validated pharmaceutical-grade product carrying documented purity data for the most sensitive regulatory applications. Margin economics differ sharply across these tiers, reflecting documentation depth and buyer urgency. Suppliers investing earliest in the hardest categories increasingly capture the richest margin pools available.
Suppliers face a genuine strategic tension between defending mature standard aquafeed volume and reallocating refining capacity toward documented pharmaceutical-grade format that offers stronger long-term growth prospects. Those building capability across all three tiers capture the widest addressable revenue base, though doing so requires deliberate strategic repositioning and sustained investment most smaller organizations struggle to fund. Capital constraints create real tension here.

High-value margin pools concentrate overwhelmingly in pharmaceutical-grade, validated documented product, where regulatory and nutraceutical buyers pay materially more for documented purity than standard aquafeed buyers require. Suppliers positioned to serve this tier alongside stable standard volume capture the clearest path toward sustained revenue as UK pharmaceutical demand continues its steady expansion across most major consumer segments.

Volume / Commodity-Adjacent Tier

Standard undocumented commodity-grade material sold into broad conventional aquafeed and animal feed applications at competitive pricing with thinner supplier margins overall. Suppliers compete here mainly on reliable supply and landed cost rather than documentation.
Gross Margin: 7-13%

Premium / Certified Tier

Premium documented product commanding meaningful certification premiums for nutraceutical and food fortification formulation requiring documented catch content and consistent batch-tested performance data. Suppliers here maintain closer relationships with premium buyer customers directly and consistently.
Gross Margin: 16-23%

Sustainability / Regulatory / Next-Generation Tier

Next-generation validated pharmaceutical-grade product carrying documented purity data for the most sensitive prescription and regulatory applications. Building credibility in this tier typically takes suppliers years of validated testing and buyer trust.
Gross Margin: 23-31%
united-kingdom-fish-oil-market-portfolio-architecture-1790209933813

High-value Sub-segments and Strategic Watch-out

Pharmaceutical Validated Purity Grade Supply

Pharmaceutical-grade validated purity supply commands the strongest margins in the category and continues growing fastest as buyers seek documented performance credibly and consistently. Suppliers serving this tier increasingly compete on validated technical data rather than price alone. Growth here should outpace every other tier ahead comfortably.
Gross Margin: 23-31%

Premium Documented Certified Nutraceutical Supply

Premium documented certified nutraceutical grade material sustains strong growth as brand owners increasingly require documented content matching regulatory expectations closely and consistently across most consumer categories today. Suppliers lagging here risk losing preferred allocation to faster-moving rivals across most channels and going forward steadily overall.
Gross Margin: 16-23%

Standard Undocumented Commodity Aquafeed Supply

Standard undocumented commodity-grade aquafeed supply continues anchoring a meaningful share of national volume even as newer, higher-margin documented tiers expand steadily across the category. Suppliers rely on this volume to fund investment in higher-margin capability elsewhere entirely. Growth here should remain modest but stable ahead.
Gross Margin: 7-13%

Anchoveta Quota Volatility Risk Exposure

Continued dependence on El Nino-affected anchoveta catch supply could meaningfully constrain UK production economics if quota or climate disruptions intensify unexpectedly and severely across major sourcing regions and fleet networks worldwide today and going forward. Suppliers with diversified sourcing face comparatively less exposure overall today and going forward steadily.

Sustainable Catch Validation Anchors Repeat Sourcing

Once a buyer validates a specific supplier's fish oil within an approved pharmaceutical or aquafeed formulation, switching suppliers requires requalifying through new sustainable-catch and purity performance testing processes, creating a genuine annuity dynamic for suppliers who secure this relationship first. Requalification costs discourage casual switching between qualified suppliers. Long-term supply contracts anchor this revenue base. Suppliers who secure this validated relationship first tend to retain it for years.
Adoption depth varies meaningfully by end-use vertical. Pharmaceutical and Scottish aquafeed formulators exhibit the deepest stickiness given extensive documentation and requalification requirements, while mainstream commodity purchasing shows comparatively shallower stickiness since buyers can rebid pilot-stage contracts more freely without the same technical requalification burden. Pharmaceutical buyers show the deepest stickiness, while commodity accounts increasingly shop purely on price.

A younger generation of formulation and procurement managers increasingly evaluates fish oil sourcing decisions through a documented-sustainable-catch-first lens by default, favoring suppliers with verified traceability consistency over undocumented commodity-grade suppliers competing purely on established cost advantages. This shift favors suppliers with documented sustainable catch over commodity suppliers competing purely on cost. Younger procurement teams now weigh documentation depth alongside price, a shift older cohorts rarely prioritized this heavily.
united-kingdom-fish-oil-market-end-use-penetration-index-1790209934122

Where Supplier Strategy Should Focus Next

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / AQUAFEED FORMAT PIVOT PRIORITY

Redirect strategic investment toward aquafeed grades

Aquafeed grade fish oil demand represents the fastest-growing, most attractive segment in this market, while conventional pharmaceutical-only demand offers only modest incremental growth regardless of pricing strategy adjustments made by suppliers today. Suppliers investing in documented concentration consistency now position themselves to capture this durable growth before more competitors recognize the opportunity, since building comparable documented consistency from scratch typically takes considerable time to establish credibly. Suppliers who move first lock in the strongest early formulator relationships in this rapidly expanding category overall.
02 / DOCUMENTATION INVESTMENT PRIORITY

Build standardized sustainable catch documentation

Documented, standardized sustainable-catch traceability increasingly determines which suppliers win the largest premium buyer contracts, rewarding documentation investment over suppliers still selling undocumented commodity-grade supply into increasingly sophisticated pharmaceutical categories. Suppliers investing in chain-of-custody infrastructure now position themselves to capture this segment before more competitors develop comparable documentation depth, since establishing trusted testing credibility typically requires considerable time and consistent batch validation. Early movers in documentation will hold a durable positioning advantage over slower-moving competitors well into the next several years.
03 / PHARMACEUTICAL EXPANSION PRIORITY

Build dedicated pharmaceutical formulation support

Pharmaceutical grade fish oil demand continues expanding steadily, representing a genuine growth opportunity beyond conventional aquafeed applications where competitive dynamics are comparatively mature and well established across most channels and price tiers. Suppliers building dedicated documentation now position themselves to capture this segment before competitors develop comparable formulation depth, since establishing trusted buyer relationships typically requires considerable time and consistent quality delivery across multiple product cycles. Early movers in pharmaceutical expansion will hold a durable positioning advantage well into the next decade.
04 / FISHERY RESILIENCE PRIORITY

Diversify catch fishery sourcing across regions now

Concentrated Norwegian sourcing leaves suppliers exposed to price and quota risk specific to individual fishing regions, a vulnerability that could meaningfully disrupt supply during any future adverse quota reduction or climate disruption. Suppliers building meaningful sourcing relationships across additional fishing regions now reduce this concentration exposure before any future disruption arrives, since developing reliable alternative sourcing relationships typically requires multiple seasons to establish trust and consistent quality. Early movers on diversification will hold a durable resilience advantage over slower-moving competitors.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
UK Fish Oil Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on UK Fish Oil Exposure Evaluation 2025-26
CLIENT PROFILE
The client is a Scottish aquafeed formulator seeking to reformulate its premium salmon feed line around documented sustainable-catch fish oil sourcing within an eight-month timeline. Annual revenue for the client's relevant product line sits in the tens of millions of pounds (client-reported, unverified by MMA). Leadership needed a defensible strategy given intensifying regulatory scrutiny from UK feed-safety authorities.
STRATEGIC CHALLENGE
The client needed to determine which Norwegian or Peruvian processor could provide sufficiently documented catch and sustainability data to support premium feed regulatory claims credibly, while confirming the resulting production cost could be absorbed within its target pricing structure without eroding profitability. Leadership also needed clear visibility into long-term supplier reliability across sourcing regions.
MMA APPROACH
MMA conducted a comparative capability assessment benchmarking three qualified European and South American processors against the client's documentation, sustainability, and cost requirements for its planned feed reformulation directly and comprehensively across every relevant criterion. The engagement ran across seven weeks and drew on processor technical data review alongside direct competitor product benchmarking and analysis.
KEY FINDINGS
  1. Comparative testing confirmed that two of the three evaluated processors could provide documentation sufficient to support the client's premium feed regulatory claims credibly and reliably.
  2. Cost impact analysis indicated that the documented sustainable-catch process would increase per-unit feed cost by an amount the client's target pricing could absorb without material margin erosion.
  3. Competitive positioning analysis showed that documented sustainable-catch traceability would meaningfully differentiate the client's feed line from competitors still using undocumented processes currently. Buyers confirmed this directly during evaluation.
  4. Supplier disclosure review confirmed both shortlisted processors maintained sufficient processing capacity and documentation depth to support the client's anticipated volume growth reliably.
CLIENT PROFILE
The client is a Scottish aquafeed formulator seeking to reformulate its premium salmon feed line around documented sustainable-catch fish oil sourcing within an eight-month timeline. Annual revenue for the client's relevant product line sits in the tens of millions of pounds (client-reported, unverified by MMA). Leadership needed a defensible strategy given intensifying regulatory scrutiny from UK feed-safety authorities.
STRATEGIC CHALLENGE
The client needed to determine which Norwegian or Peruvian processor could provide sufficiently documented catch and sustainability data to support premium feed regulatory claims credibly, while confirming the resulting production cost could be absorbed within its target pricing structure without eroding profitability. Leadership also needed clear visibility into long-term supplier reliability across sourcing regions.
MMA APPROACH
MMA conducted a comparative capability assessment benchmarking three qualified European and South American processors against the client's documentation, sustainability, and cost requirements for its planned feed reformulation directly and comprehensively across every relevant criterion. The engagement ran across seven weeks and drew on processor technical data review alongside direct competitor product benchmarking and analysis.
KEY FINDINGS
  1. Comparative testing confirmed that two of the three evaluated processors could provide documentation sufficient to support the client's premium feed regulatory claims credibly and reliably.
  2. Cost impact analysis indicated that the documented sustainable-catch process would increase per-unit feed cost by an amount the client's target pricing could absorb without material margin erosion.
  3. Competitive positioning analysis showed that documented sustainable-catch traceability would meaningfully differentiate the client's feed line from competitors still using undocumented processes currently. Buyers confirmed this directly during evaluation.
  4. Supplier disclosure review confirmed both shortlisted processors maintained sufficient processing capacity and documentation depth to support the client's anticipated volume growth reliably.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (Months 1 to 2): Finalize processor selection and negotiate supply contract terms and volume commitments carefully and thoroughly. Phase 2: Phase 2 (Months 3 to 6): Reformulate the salmon feed line and validate sustainable-catch performance against the target baseline closely. Phase 3: Phase 3 (Months 7 to 8): Launch the reformulated feed line and monitor performance against the client's existing benchmarks closely.
OUTCOME
The client launched its reformulated salmon feed line on schedule and reported feed-conversion performance meaningfully ahead of its existing benchmarks within the first two quarters following launch (client-reported, unverified by MMA). The reformulated line has since become the client's standard flagship formulation across its full production network.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the UK Fish Oil Market?

UK demand reached approximately USD 0.58 billion in 2025. This reflects United Kingdom demand for fish oil across pharmaceutical, aquafeed, and nutraceutical applications across most channels today.

How large will the UK Fish Oil Market be by 2036?

UK demand is projected to reach approximately USD 1.1476 billion by 2036, up from USD 0.6171 billion in 2026. This reflects an incremental expansion of roughly USD 0.5305 billion over the forecast period.

What is the CAGR for the UK Fish Oil Market 2026 to 2036?

UK demand is forecast to grow at a 6.4% CAGR between 2026 and 2036. Bull and bear scenarios range from 7.7% to 5.1% depending on adoption outcomes.

Which segment is growing fastest?

Aquafeed grade fish oil leads at a 9.6% CAGR, roughly 1.50 times the overall market rate, with pharmaceutical grade fish oil close behind at 8.4%.

Who are the major companies in the UK Fish Oil Market?

Leading suppliers include Croda International, Austevoll Seafood, Pelagia, Skretting, and BioMar, each with substantial refining capacity. These five companies hold a combined market share of approximately 36 percent.

Which country is growing fastest?

Norway grows fastest at an 8.9% CAGR, ahead of the broader Western Europe average, reflecting expanding reduction-fishery capacity and rising documented traceability requirements across markets.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Grade Type

  • Pharmaceutical Grade Fish Oil
  • Nutraceutical and Dietary Supplement Grade
  • Aquafeed Grade Fish Oil
  • Animal Feed Grade Fish Oil
  • Food Fortification Grade Fish Oil
  • Industrial Technical Grade Fish Oil

By End-Use Industry

  • Pharmaceutical and Prescription Manufacturing
  • Nutraceutical and Supplement Manufacturing
  • Aquaculture and Animal Feed Manufacturing
  • Food and Beverage Fortification

By Commercial Dimension

  • Direct Manufacturer Supply Agreements
  • Contract Refining Support Services
  • Distributor and Import Channel
  • Private-Label Formulation Programs

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, September 2026)
Market Definition
This report defines the UK fish oil market as United Kingdom demand for fish oil used in pharmaceutical, nutraceutical, aquafeed, animal feed, and food fortification applications, tracking the global sourcing regions that supply this demand. It excludes algae-derived and other non-fish marine oil alternatives, covered in a separate MMA report on alternative omega-3 ingredients.
Quantitative Units
USD billions (current prices); documentation premium as percentage of undocumented commodity-grade equivalent cost
Segmentation Dimensions
By Grade Type; By End-Use Industry; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
United Kingdom, Norway, Iceland, Denmark, Peru, Chile, Ecuador, Morocco, South Africa, Mauritania, China, Japan, India, Australia, United States, Canada, Poland, Lithuania, Latvia, Russia, and additional markets relevant to this sector
Key Companies Profiled
Croda International Plc, Austevoll Seafood ASA, Pelagia AS, Skretting AS, BioMar Group, Mowi Scotland Ltd, Scottish Sea Farms Ltd, Cargill Incorporated, Nutreco N.V., TASA, Copeinca ASA, GC Rieber Oils AS, Epax Norway AS, KD Pharma Group, DSM-Firmenich AG, Golden Omega S.A., Marine Ingredients Norway AS, Grieg Seafood ASA, Cooke Aquaculture Scotland Ltd, Bakkafrost Scotland Ltd
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-AGR-124
Published
September 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full UK Fish Oil Market Report (2026 to 2036).

This report delivers a complete commercial assessment of the UK fish oil market, covering sizing, segmentation, and global sourcing distribution through 2036, with particular analytical focus on documented sustainable-catch traceability and Scottish aquafeed channel adoption trends. It profiles twenty suppliers serving pharmaceutical, aquafeed, and nutraceutical categories, detailing competitive positioning, sustainability certification, and raw fish sourcing exposure. Analysis extends to raw fish cost exposure and mitigation pathways, and portfolio margin economics across three commercial tiers. Bull and bear forecast scenarios are modeled explicitly against named commercial catalysts and clearly identified supply risks facing the industry.
Ten-year sizing and forecast model through 2036
Six-segment grade type breakdown and analysis
Seven-region sourcing distribution and share analysis
Twenty-company competitive profile and positioning assessments
Raw fish cost exposure and volatility assessment
Portfolio tier margin economics and pricing analysis

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts